Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension

---

Onal E. M., Sag A. A., Sal O., Yerlikaya A., AFŞAR B., Kanbay M.

CLINICAL AND EXPERIMENTAL HYPERTENSION, vol.39, no.3, pp.197-209, 2017 (SCI-Expanded, Scopus)

• Publication Type: Article / Review
• Volume: 39 Issue: 3
• Publication Date: 2017
• Doi Number: 10.1080/10641963.2016.1246565
• Journal Name: CLINICAL AND EXPERIMENTAL HYPERTENSION
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.197-209
• Istanbul University Affiliated: No

Abstract

Organ crosstalk pathways represent the next frontier for target-mining in molecular medicine for existing syndromes. Pulmonary hypertension and resistant essential hypertension are syndromes that have been proven elusive in etiology, and frequently refractory to first-line management. Underlying crosstalk mechanisms, not yet considered in these treatments, may hinder outcomes or unlock novel treatments. This review focuses systematically on erythropoietin, a synthesizable molecule, as a mediator of brain-kidney crosstalk. Insights gained from this review will be applied to cardiovascular diseases in a clinician-directed fashion.